Annals of the Russian academy of medical sciencesAnnals of the Russian academy of medical sciences0869-60472414-3545"Paediatrician" Publishers LLC200610.15690/vramn2006Review ArticleNon-Invasive Prenatal Testing: the International Experience of Medical and Economic NIPT Efficiency EvaluationKaplanovaMadina T.<p>MD</p>kaplanova@evogenlab.ruhttps://orcid.org/0000-0001-6715-706XGalaktionovaAlexandra M.<p>MD, PhD</p>galaktionova@evogenlab.ruhttps://orcid.org/0000-0001-8602-5441BaranovaElena E.<p>MD, PhD</p>baranova@evogenlab.ruhttps://orcid.org/0000-0001-9638-2303SagaydakOlesya V.<p>MD, PhD</p>sagaydak@evogenlab.ruhttps://orcid.org/0000-0002-2534-8463BelenikinMaksim S.<p>PhD in Chemical</p>belenikin@evogenlab.ruhttps://orcid.org/0000-0002-6556-163XDenisovAlexey G.<p>MD, PhD</p>denisovag@yandex.ruLLC “Evogen”Russian Medical Academy of Continuous Professional EducationHealth Department of the Yamalo-Nenets Autonomous OkrugSalekhard District Clinical Hospital141120227742762841802202204102022Copyright © 2022, "Paediatrician" Publishers LLC2022<p>Non-invasive prenatal testing (NIPT) is a molecular genetic method of cell-free fetal DNA fetal chromosomal abnormalities risks assessing. Currently, NIPT is quite widespread throughout the world, and its clinical efficacy high sensitivity and specificity has been repeatedly proven. At the same time, the decision to include NIPT in the algorithm of prenatal diagnostics carried out with public funds depends on its cost-effectiveness, which should be assessed separately for each country or territory due to different costs and different models of inclusion. This article presents the different countries approaches to the assessment of the medical and economic efficiency of NIPT.</p>noninvasive prenatal testingprenatal diagnosisinvasive prenatal diagnosischromosomal abnormalitiescost effectiveness analysisнеинвазивное пренатальное тестированиепренатальная диагностикаинвазивная пренатальная диагностикахромосомные аномалииэкономическая эффективность[Оленев А.С., Баранова Е.Е., Сагайдак О.В., и др. Международный опыт организации проведения неинвазивного пренатального теста // Вопросы гинекологии, акушерства и перинатологии. — 2021. — Т. 20. — № 1. — С. 129–137. [Olenev AS, Baranova EE, Sagaydak OV, et al. International experience in organizing non-invasive prenatal testing. Vopr. ginekol. akus. perinatol. (Gynecology, Obstetrics and Perinatology). 2021;20(1):129–137. (In Russ.)] doi: https://doi.org/10.20953/1726-1678-2021-1-129-137][Ghi T, Sotiriadis A, Calda P, et al. ISUOG Practice Guidelines: invasive procedures for prenatal diagnosis. Ultrasound Obstet Gynecol. 2016;48(2):256–268. doi: https://doi.org/10.1002/uog.15945][Allyse M, Minear MA, Berson E, et al. Non-invasive prenatal testing: a review of international implementation and challenges. Int J Womens Health. 2015;16(7):113–126. doi: https://doi.org/10.2147/IJWH.S67124][Minear MA, Alessi S, Allyse M, et al. Noninvasive Prenatal Genetic Testing: Current and Emerging Ethical, Legal, and Social Issues. Annu Rev Genomics Hum Genet. 2015;16:369–398. doi: https://doi.org/10.1146/annurev-genom-090314-050000][Gadsbøll K, Petersen OB, Gatinois V, et al. Current use of noninvasive prenatal testing in Europe, Australia and the USA: A graphical presentation. Acta Obstet Gynecol Scand. 2020;99(6):722–730. doi: https://doi.org/10.1111/aogs.13841][Ayres AC, Whitty JA, Ellwood DA. A cost‐effectiveness analysis comparing different strategies to implement noninvasive prenatal testing into a Down syndrome screening program. Aust N Z J Obstet Gynaecol. 2014;54(5):412–417. doi: https://doi.org/10.1111/ajo.12223][Prefumo F, Paolini D, Speranza G, et al. The contingent use of cell-free fetal DNA for prenatal screening of trisomies 21, 18, 13 in pregnant women within a national health service: A budget impact analysis. PLoS One. 2019;14(6):e0218166. doi: https://doi.org/10.1371/journal.pone.0218166][Screening del DNA fetale non invasivo (NIPT) in sanità pubblica / Consiglio Superiore di Sanità Sessione LII Ministero della Salute (2019–2022). Presidente: Prof. F. Locatelli. Sezione I. Presidente: Prof. B. Dallapiccola. (In Ital.)][Kostenko E, Chantraine F, Vandeweyer K, et al. Clinical and Economic Impact of Adopting Noninvasive Prenatal Testing as a Primary Screening Method for Fetal Aneuploidies in the General Pregnancy Population. Fetal Diagn Ther. 2019;45(6):413–423. doi: https://doi.org/10.1159/000491750][Dougan ShD, Okun N, Bellai-Dussault K, et al. Performance of a universal prenatal screening program incorporating cell-free fetal DNA analysis in Ontario, Canada. CMAJ. 2021;193(30):E1156–E1163. doi: https://doi.org/10.1503/cmaj.202456][Xie X, Wang M, Goh ES-Y, et al. Noninvasive Prenatal Testing for Trisomies 21, 18, and 13, Sex Chromosome Aneuploidies, and Microdeletions in Average-Risk Pregnancies: A Cost-Effectiveness Analysis. J Obstet Gynecol Can. 2020;42(6):740–749. doi: https://doi.org/10.1016/j.jogc.2019.12.007][Zhang W, Mohammadi T, Sou J, et al. Cost-effectiveness of prenatal screening and diagnostic strategies for Down syndrome: A microsimulation modeling analysis. PLoS One. 2019;14(12):e0225281. doi: https://doi.org/10.1371/journal.pone.0225281][Nshimyumukiza L, Beaumont JA, Rousseau F, et al. Introducing cell-free DNA noninvasive testing in a Down syndrome public health screening program: a budget impact analysis. Cost Eff Resour Alloc. 2020;18(1):49. doi: https://doi.org/10.1186/s12962-020-00245-5][Van der Meij KRM, Sistermans EA, Macville MVE, et al. TRIDENT-2: National Implementation of Genome-wide Non-invasive Prenatal Testing as a First-Tier Screening Test in the Netherlands. Am J Hum Genet. 2019;105(6):1091–1101. doi: https://doi.org/10.1016/j.ajhg.2019.10.005][Beulen L, Grutters JP, Faas BH, et al. The consequences of implementing non-invasive prenatal testing in Dutch national health care: a cost-effectiveness analysis. Eur J Obstet Gynecol Reprod Biol. 2014;182:53–61. doi: https://doi.org/10.1016/j.ejogrb.2014.08.028][Wang Sh, Liu K, Yang H, et al. A Cost-Effectiveness Analysis of Screening Strategies involving Noninvasive Prenatal Testing for Trisomy 21. January 2020. doi: https://doi.org/10.21203/rs.2.20761/v1][Емельяненко Е.С., Ветрова Н.В., Масюк С.В., и др. Клиническая и экономическая эффективность методов пренатальной диагностики хромосомных аномалий // Доктор.Ру. Гинекология. Эндокринология. — 2016. — № 3 (120). — С. 43–51. [Emeliaynenko ES, Vetrova NV, Masyuk SV. Prenatal Diagnosis of Chromosomal Abnormalities: Clinical- and Cost-Effectiveness Doctor.Ru. Gynecology. Endocrinology. 2016;3(120):43–51. (In Russ.)]][Приказ Департамента здравоохранения Ямало-Ненецкого автономного округа от 24.06.2020 № 671-о «Об организации проведения неинвазивного пренатального теста (НИПТ) в Ямало-Ненецком автономном округе». [Prikaz Departamenta zdravoohraneniya Yamalo-Neneckogo avtonomnogo okruga ot 24.06.2020 No. 671-o “Ob organizacii provedeniya neinvazivnogo prenatal’nogo testa (NIPT) v Yamalo-Neneckom avtonomnom okruge”. (In Russ.)]][Приказ Департамента здравоохранения Ямало-Ненецкого автономного округа от 29.04.2021 № 444-о «Об организации проведения неинвазивного пренатального теста (НИПТ) в Ямало-Ненецком автономном округе». [Prikaz Departamenta zdravoohraneniya Yamalo-Neneckogo avtonomnogo okruga ot 29.04.2021 No. 444-o “Ob organizacii provedeniya neinvazivnogo prenatal’nogo testa (NIPT) v Yamalo-Neneckom avtonomnom okruge”. (In Russ.)]][Приказ Департамента здравоохранения Ямало-Ненецкого автономного округа от 01.07.2021 № 643-о «О внесении изменений в приказ департамента здравоохранения Ямало-Ненецкого автономного округа от 29 апреля 2021 года № 444-о». [Prikaz Departamenta zdravoohraneniya Yamalo-Neneckogo avtonomnogo okruga ot 01.07.2021 No. 643-o “O vnesenii izmenenij v prikaz departamenta zdravoohraneniya Yamalo-Neneckogo avtonomnogo okruga ot 29 aprelya 2021 goda No. 444-o”. (In Russ.)]][Приказ Департамента здравоохранения города Москвы от 13.03.2020 № 199 «Об организации проведения неинвазивного пренатального теста в городе Москве». [Prikaz Departamenta zdravoohraneniya goroda Moskvy ot 13.03.2020 No. 199 “Ob organizacii provedeniya neinvazivnogo prenatal’nogo testa v gorode Moskve”. (In Russ.)]][Samura O. Update on noninvasive prenatal testing: A review based on current worldwide research. J Obstet Gynaecol Res. 2020;46(8):1246–1254. doi: https://doi.org/10.1111/jog.14268][Nicolaides KH, Syngelaki A, del Mar Gil M, et al. Prenatal detection of fetal triploidy from cell-free DNA testing in maternal blood. Fetal Diagn Ther. 2014;35(3):212–217. doi: https://doi.org/10.1159/000355655][Gil MM, Quezada MS, Revello R, et al. Analysis of cell-free DNA in maternal blood in screening for fetal aneuploidies: updated meta-analysis. Ultrasound Obstet Gynecol. 2015;45(3):249–266. doi: https://doi.org/10.1002/uog.14791]